Pharmacokinetics– tag –
-
PROTAC Research Shifts to Structural Design, Oral Bioavailability, and AI-Driven Approaches: Bibliometric Analysis Reveals Emerging Frontiers and Pivotal Trial Era
PubMed USA Overview A bibliometric analysis of 2,630 PROTAC publications from 2001-2025 reveals a shift from early E3 ligase recruitment research to current hotspots including structural basis, ternary complex design, EGFR-directed degra... -
FDA Approves First PROTAC Vepdegestrant (ARV-471) for ER+/HER2- Breast Cancer, Ushering in a New Era of Targeted Protein Degradation
Journal of Medicinal Chemistry - ACS Publications USA Overview On May 1, 2026, the FDA approved vepdegestrant (ARV-471; Veppanu), making it the first heterobifunctional PROTAC protein degrader approved for clinical practice. Indicated fo... -
Exponential Progression in Targeted Protein Degradation (TPD) Drug Discovery: New Modality Accelerates Drug Development
MarinBio USA Overview MarinBio published an article highlighting the exponential progression in Targeted Protein Degradation (TPD) drug discovery, establishing it as a primary, accelerating modality in novel drug development. TPD technol... -
Exponential Progression of Targeted Protein Degradation: First FDA-Approved PROTAC and Molecular Glues Unlock “Undruggable” Targets
MarinBio (Appears to be a scientific review/journal, affiliated with MarinBio, hence using their domain) USA Overview The field of targeted protein degradation (TPD) is rapidly evolving, enabling the degradation of previously "undruggabl... -
Oral GLP-1 Agonist Semaglutide Success Drives Peptide Drug Discovery Transformation: AI Design, Unnatural Amino Acids, and Nanocarriers Enhance Oral Bioavailability
Bhunia Lab Unknown Overview While peptide therapeutics have advanced significantly, oral delivery remains a challenge. The success of oral semaglutide demonstrates how chemical modifications like amino acid substitutions and fatty acid a... -
Constructive Bio Develops Oral Peptide Pipeline with Novel Membrane Permeability via Unnatural Amino Acids, Advancing ADCs with Genetic Code Expansion for Injectable-to-Oral Shift
Constructive Bio Unknown Overview Constructive Bio is developing a pipeline of oral peptide therapeutics using unnatural amino acids to enable oral bioavailability for drugs previously requiring injection. These engineered peptides featu... -
FDA Approves Oral Peptide Icorokinra for Moderate-to-Severe Plaque Psoriasis, Driven by Advanced DDS
Dermatology Times USA Overview The FDA has approved icorokinra, the first oral IL-23 receptor antagonist peptide for moderate-to-severe plaque psoriasis, representing a significant breakthrough in oral peptide delivery systems (DDS). Thi...
12